• Home
  •  / Bristol-Myers Squibb

Bristol-Myers Squibb

OverviewSuggest Edit

Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious and life-threatening diseases. Its medicines help patients in disease areas such as oncology, cardiovascular, immunoscience, fibrosis, and others.
TypePublic
Founded1887
HQNew York, NY, USMap
Websitebms.com
Employee Ratings4More
Overall CultureAMore
View Jobs (3)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)30,000(+29%)
Job Openings3
Revenue (FY, 2019)$26.1 B(+16%)
Share Price (Jan 2021)$66.5
Cybersecurity ratingBMore

Key People/Management at Bristol-Myers Squibb

Giovanni Caforio

Giovanni Caforio

Chairman of the Board and Chief Executive Officer
Jeff Staiger

Jeff Staiger

Vice President, Cardiovascular, Fibrosis, Immunology, Neuroscience Business Development
Rupert Vessey

Rupert Vessey

Executive Vice President and President, Research and Early Development
Brian Heaphy

Brian Heaphy

Vice President, Corporate Development
Sandra Leung

Sandra Leung

Executive Vice President, General Counsel
Nadim Ahmed

Nadim Ahmed

Executive Vice President and President, Hematology
Show more

Bristol-Myers Squibb Office Locations

Bristol-Myers Squibb has offices in New York, Atlanta, Baltimore, Cambridge and in 49 other locations
New York, NY, US (HQ)
345 Park Avenue, 345 Park Ave
Atlanta, GA, US
950 East Paces Ferry Rd NE
Baltimore, MD, US
Baltimore, MD, USA
Cambridge, MA, US
100 Binney St
Columbus, OH, US
999 Polaris Pkwy #100
Devens, MA, US
38 Jackson Rd
Show all (55)

Bristol-Myers Squibb Financials and Metrics

Bristol-Myers Squibb Revenue

Embed Graph
View revenue for all periods
Bristol-Myers Squibb's revenue was reported to be $26.15 b in FY, 2019 which is a 15.9% increase from the previous period.
USD

Revenue (Q3, 2020)

10.5b

Gross profit (Q3, 2020)

8.0b

Gross profit margin (Q3, 2020), %

76.3%

Net income (Q3, 2020)

1.9b

Market capitalization (15-Jan-2021)

150.4b

Closing stock price (15-Jan-2021)

66.5

Cash (30-Sept-2020)

19.4b

EV

175.9b
Bristol-Myers Squibb's current market capitalization is $150.4 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

20.8b22.6b26.1b

Revenue growth, %

7%9%16%

Cost of goods sold

6.1b6.5b8.1b

Gross profit

14.7b16.0b18.1b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.2b5.7b5.7b5.9b6.3b6.0b10.8b10.1b10.5b

Cost of goods sold

1.6b1.6b1.6b1.8b2.0b1.8b3.7b2.7b2.5b

Gross profit

3.6b4.1b4.0b4.1b4.3b4.2b7.1b7.4b8.0b

Gross profit Margin, %

69%72%71%69%68%70%66%73%76%
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

5.4b6.9b12.3b

Accounts Receivable

6.3b6.0b7.7b

Prepaid Expenses

576.0m

Inventories

1.2b1.2b4.3b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

5.3b5.0b5.4b7.3b28.4b30.5b15.8b19.9b19.4b

Accounts Receivable

5.7b5.6b5.9b5.7b5.7b5.5b8.3b7.9b8.1b

Prepaid Expenses

965.0m998.0m886.0m

Inventories

1.2b1.2b1.3b1.3b1.3b1.2b2.8b2.4b1.9b
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

975.0m4.9b3.5b

Depreciation and Amortization

789.0m637.0m1.7b

Inventories

(29.0m)(216.0m)463.0m

Accounts Payable

320.0m(59.0m)229.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

1.5b1.9b3.8b1.7b3.2b4.5b(766.0m)(846.0m)1.0b

Depreciation and Amortization

143.0m300.0m465.0m223.0m443.0m510.0m2.6b5.0b7.7b

Inventories

(4.0m)(122.0m)(152.0m)35.0m28.0m(7.0m)1.4b2.1b2.6b

Accounts Payable

(241.0m)(101.0m)(186.0m)136.0m156.0m48.0m703.0m480.0m56.0m
show all
USDFY, 2017

EV/CFO

19.5 x

Revenue/Employee

876.6k

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

2.8 x

P/E Ratio

100.5
Show all financial metrics

Bristol-Myers Squibb Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Manufacturing Facilities

6 7 7

Phase I Trials Products (Hematology)

14

Projects in R&D Pipeline

32 44

Research and Development Centers

7 7 12
Show all operating metrics

Bristol-Myers Squibb Acquisitions / Subsidiaries

Company NameDateDeal Size
MyoKardiaOctober 05, 2020$13.10 b
ForbiusAugust 24, 2020
CelgeneJanuary 03, 2019$74 b
IFM TherapeuticsAugust 03, 2017
Cormorant PharmaceuticalsJuly 05, 2016
Padlock TherapeuticsMarch 23, 2016$600 m
Cardioxyl PharmaceuticalsNovember 02, 2015$2 b
Flexus BiosciencesFebruary 23, 2015$1.25 b
Galecto BiotechNovember 03, 2014$444 m
F-star AlphaOctober 28, 2014$475 m
Show more

Bristol-Myers Squibb Revenue Breakdown

Embed Graph

Bristol-Myers Squibb revenue breakdown by business segment: 30.3% from Eliquis, 27.6% from Opdivo, 11.4% from Orencia, 8.1% from Sprycel, 5.7% from Yervoy, 6.4% from Other Brands and 10.6% from Other

Bristol-Myers Squibb revenue breakdown by geographic segment: 58.7% from United States, 24.0% from Europe, 15.3% from Rest of World and 2.0% from Other

Bristol-Myers Squibb Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

Bristol-Myers Squibb Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

Learn more about our premium products
CSRHub logo

Bristol-Myers Squibb Online and Social Media Presence

Bristol-Myers Squibb's Trends

Embed Graph

Bristol-Myers Squibb Company Culture

  • Overall Culture

    A

    76/100

  • CEO Rating

    A+

    81/100

  • Compensation

    A+

    85/100

  • Diversity

    A+

    79/100

Learn more on Comparably

Bristol-Myers Squibb News and Updates

January 11, 2021

Global Castrate Resistant Prostate Cancer Pipeline Insight Report 2020 Featuring Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma & ESSA Pharma

Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The "Castrate Resistant Prostate Cancer - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
December 11, 2020

Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Inrebic® (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with …
December 08, 2020

Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced it has entered into a clinical collaboration agreement…
December 07, 2020

Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission

Bristol Myers Squibb (NYSE: BMY) today announced new results from the QUAZAR® AML-001 study presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, evaluating Onureg®(azacitidine tablets; CC-486), an oral hypomethylating agent, as a treatment for adult patients with…
December 07, 2020

Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020

Bristol Myers Squibb (NYSE: BMY) today announced data from multiple studies evaluating lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T cell therapy, in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SL…
December 05, 2020

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data evaluating the companies’ investigational B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel), were presented at the 62nd Americ…
Show more

 Bristol-Myers Squibb Frequently Asked Questions

  • When was Bristol-Myers Squibb founded?

    Bristol-Myers Squibb was founded in 1887.

  • Who are Bristol-Myers Squibb key executives?

    Bristol-Myers Squibb's key executives are Giovanni Caforio, Jeff Staiger and Rupert Vessey.

  • How many employees does Bristol-Myers Squibb have?

    Bristol-Myers Squibb has 30,000 employees.

  • What is Bristol-Myers Squibb revenue?

    Latest Bristol-Myers Squibb annual revenue is $26.1 b.

  • What is Bristol-Myers Squibb revenue per employee?

    Latest Bristol-Myers Squibb revenue per employee is $871.5 k.

  • Who are Bristol-Myers Squibb competitors?

    Competitors of Bristol-Myers Squibb include Daiichi Sankyo, Regeneron Pharmaceuticals and Gilead Sciences.

  • Where is Bristol-Myers Squibb headquarters?

    Bristol-Myers Squibb headquarters is located at 345 Park Avenue, 345 Park Ave, New York.

  • Where are Bristol-Myers Squibb offices?

    Bristol-Myers Squibb has offices in New York, Atlanta, Baltimore, Cambridge and in 49 other locations.

  • How many offices does Bristol-Myers Squibb have?

    Bristol-Myers Squibb has 55 offices.